Results of Operations · Company Update

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported):  October 14, 2025 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 1-3215 22-1024240 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) One Johnson & Johnson Plaza , New Brunswick , New Jersey    08933   (Address of Principal Executive Offices)  (Zip Code)  Registrant's telephone number, including area code: 732 - 524-0400 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, Par Value $1.00 JNJ New York Stock Exchange 1.150% Notes Due November 2028 JNJ28 New York Stock Exchange 2.700% Notes due February 2029 JNJ29B New York Stock Exchange 3.200% Notes Due June 2032 JNJ32 New York Stock Exchange 3.050% Notes due February 2033 JNJ33B New York Stock Exchange 1.650% Notes Due May 2035 JNJ35 New York Stock Exchange 3.350% Notes Due June 2036 JNJ36A New York Stock Exchange 3.350% Notes due February 2037 JNJ37B New York Stock Exchange 3.550% Notes Due June 2044 JNJ44 New York Stock Exchange 3.600% Notes due February 2045 JNJ45 New York Stock Exchange 3.700% Notes due February 2055 JNJ55 New York Stock Exchange Item 2.02 Results of operations and financial condition On October 14, 2025, Johnson & Johnson (the “Company”) issued the attached press release (Exhibit 99.1) announcing its sales and earnings for the third quarter ended September 28, 2025. Item 8.01 Other events On October 14, 2025, the Company issued the attached press release (Exhibit 99.3) announcing its intent to separate the Company's Orthopaedics business. Item 9.01 Financial statements and exhibits (d)    Exhibits. Exhibit No. Description of Exhibit 99.1 Press Release dated October 1 4 , 2025 for the period ended September 2 8 , 2025 99.2 Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the fiscal third quarter and nine months 99.3 Press Re lease dated October 14, 2025 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 14, 2025 JOHNSON & JOHNSON (Registrant) By: /s/ Robert J. Decker, Jr. Robert J. Decker, Jr. Controller (Principal Accounting Officer)